Tessitore 2008.

Methods	Study design: pilot cross‐over RCT Study duration: NS Duration of follow‐up: 54 weeks
Participants	Country: Italy Setting: single centre Stable HD patients on IV EPO and IV iron Number: treatment group 1 (18); treatment group 2 (18) Mean age ± SD (years): NS Sex (M/F): NS Exclusion criteria: NS
Interventions	Treatment group 1 DA: 20 or 50 μg doses IV for 39 weeks; converted from EPO according to 200 U rHuEPO equivalent to 1 μg DA Treatment group 2 rHuEPO: 2000, 4000, 10,000 U for 39 weeks according to previous dose Other information Dose adjustments: NS 15 week titration and 39 week evaluation Co‐interventions IV NaFe gluconate
Outcomes	Final Hb Final rHuEPO dose
Notes	Abstract only
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	NS
Allocation concealment (selection bias)	Low risk	Coin toss
Blinding of participants and personnel (performance bias) All outcomes	Low risk	No blinding but outcome of Hb unlikely to be influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	No blinding but outcome of Hb unlikely to be influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Unclear if all patients included in analysis
Selective reporting (reporting bias)	Unclear risk	Insufficient information to permit judgement
Other bias	Unclear risk	Information not provided